SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3257Correction. I should read more and more carefully. High risk is anyone or overA.J. Mullen-3/23/2021
3256Phase III shows cocktail reduces hospitalization or death by 70% in high-risk noA.J. Mullen-3/23/2021
3255CheckmateBiotechwantabe13/23/2021
3254FDA approves Arcalyst (rilonacept) for recurrent periocarditis: investorshub.aDewDiligence_on_SI-3/18/2021
3253Nice surprise although I think I read the patient size is shrinking due to vacciFelix B-3/16/2021
3252Cemo/pd1 combo next. Would be nice to get stopped early for positive results. PBiotechwantabe13/16/2021
3251Possible competition for Dupixent a step closer, finance.yahoo.com Reuters) - AA.J. Mullen-2/26/2021
3250REGEN-COV reduces hospitalizations and deaths in outpatients Knowing all that wCuttingEdge Bio-2/25/2021
3249Yes, sanofi ROW sales suck. I’m just saying regeneron needs to do something abBiotechwantabe-2/11/2021
3248< I am starting to really hate this company> You are only +10 years late!Miljenko Zuanic22/11/2021
3247Yes, Evkeeza is a rare disease drug and doesn't really address the question.CuttingEdge Bio-2/11/2021
3246I'm not sure what you mean. Racking up sales and profits without effort is CuttingEdge Bio-2/11/2021
3245Us % of sales Q4 Keytruda. 56 Eylea 61 Dupi 79 Libtayo 76 Okay bayer doesn’t lBiotechwantabe-2/10/2021
3244Will Evkeeza be a good indicator on ROW marketing given the ultra rare indicatioFelix B-2/10/2021
3243It and bayer are bad deals because it allows them to rack in revenue/profits andBiotechwantabe-2/10/2021
3242How is it a bad deal? Who knew that Sanofi were shit?CuttingEdge Bio-2/10/2021
3241Well regeneron will get plenty of opportunity in row starting with Evkeeza. We Biotechwantabe-2/10/2021
3240Something about this slide deck irks me. When has Sanofi ever displayed any sorCuttingEdge Bio-2/9/2021
3239Cemip for BCC: finance.yahoo.comMiljenko Zuanic-2/9/2021
3238At least it is tide to stock performance, and not option trading plan...that benMiljenko Zuanic-2/9/2021
3237Sanofi capital market day Mostly about dupi/il33. Starting 1:20 China approvBiotechwantabe12/6/2021
32362021 guesstimate Dupi 4b +50% +2b Eylea 8b +10% .8b Cov2 US +3b ROW +3b (possiBiotechwantabe-2/5/2021
3235Why should any executives have of incentive-compensation packages of this magnitDewDiligence_on_SI12/5/2021
3234Dupi, small correction from REGN, US is $925.6M and ROW is $246.4M.Miljenko Zuanic-2/5/2021
3233From Sanofi 4Q results, Dupi US sale were $920M, while ex-US were $248.7M. So, tMiljenko Zuanic-2/5/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News